FDA Clears Roche's Elecsys pTau217 Blood Test for Alzheimer's Biomarker Detection
Roche has received FDA clearance for its Elecsys pTau217 assay, a blood test designed to detect phosphorylated tau 217 (pTau217), a biomarker associated with Alzheimer's disease. Developed in collaboration with Eli Lilly, this test is approved for use in patients aged 55 and older who exhibit signs of cognitive decline. The Elecsys pTau217 assay is notable as the first FDA-cleared blood test using a single biomarker that can both identify and rule out amyloid pathology, a key indicator of Alzheimer's. High levels of pTau217 suggest a greater likelihood of Alzheimer's, while lower levels can help exclude the disease, potentially reducing the need for more invasive and costly diagnostic procedures like PET scans or cerebrospinal fluid (CSF) assessments. The test is designed to operate on Roche's existing cobas laboratory platforms, which are widely installed in U.S. clinical laboratories. 
